Barinthus Biotherapeutics reported Q1 2026 results and progress on its merger with Clywedog Therapeutics, aiming to create a focused autoimmune and metabolic disease company. The Phase 1 AVALON trial of VTP-1000 for celiac disease is ongoing, with multiple ascending dose data expected in the second half of 2026. The merger is anticipated to close mid-2026, forming Clywedog Therapeutics Holdings, with a cash runway through 2027 supported by existing and new investors. The company also appointed a new CFO and reported a reduced net loss of $5.5 million for Q1 2026 compared to $19.6 million a year earlier.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
Visionstate Corp. has decided to pause its previously announced non-brokered private placement financing under the LIFE exemption, initially targeting $500,000 to $1,000,000. The company will use this time to reconsider the structure and timing of th...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Following a five-year antitrust lawsuit by Epic Games, Google will let Android users in the US download third-party apps directly from the Google Play Store starting July 22. This change comes after a court ruling that found Google's Play Store pract...
